Details for Patent: 12,005,043
Which drugs does patent 12,005,043 protect, and when does it expire?
Patent 12,005,043 protects ATTRUBY and is included in one NDA.
This patent has thirty-six patent family members in twenty-seven countries.
Summary for Patent: 12,005,043
| Title: | Formulations of AG10 |
| Abstract: | The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants. |
| Inventor(s): | Jesper Jernelius, Mark Michael MENNING |
| Assignee: | Eidos Therapeutics Inc |
| Application Number: | US17/577,479 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,005,043 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 12,005,043
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bridgebio Pharma | ATTRUBY | acoramidis hydrochloride | TABLET;ORAL | 216540-001 | Nov 22, 2024 | RX | Yes | Yes | 12,005,043 | ⤷ Start Trial | Y | TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,005,043
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019321583 | ⤷ Start Trial | |||
| Australia | 2025226697 | ⤷ Start Trial | |||
| Brazil | 112020026493 | ⤷ Start Trial | |||
| Canada | 3104695 | ⤷ Start Trial | |||
| Chile | 2021000289 | ⤷ Start Trial | |||
| China | 112804998 | ⤷ Start Trial | |||
| China | 122056844 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
